Synergistic cooperation between sunitinib and cisplatin promotes apoptotic cell death in human medullary thyroid cancer

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 2, 2014, Pages 498-509

  Lopergolo, Alessia ^a   Nicolini, Valentina ^a   Favini, Enrica ^a   Bo, Laura Dal ^a   Tortoreto, Monica ^a   Cominetti, Denis ^a   Folini, Marco ^a   Perego, Paola ^a   Castiglioni, Vittoria ^b,c   Scanziani, Eugenio ^b,c   Borrello, Maria Grazia ^a   Zaffaroni, Nadia ^a   Cassinelli, Giuliana ^a   Lanzi, Cinzia ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c Mouse and Animal Pathology Lab   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, MEDULLARY; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DRUG SYNERGISM; HUMANS; INDOLES; MICE; PROTEIN KINASE INHIBITORS; PYRROLES; THYROID NEOPLASMS;

EID: 84893789057     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-2574     Document Type: Article

References (40)

1. Frank-Raue K, Rondot S, Raue F. Molecular genetics and phenomics of RET mutations: Impact on prognosis of MTC. Mol Cell Endocrinol. 2010;322:2-7.
2. Sherman SI. Targeted therapy of thyroid cancer. Biochem Pharmacol. 2010;80:592-601.
3. Wells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012;30: 134-141.
4. Thornton K, Kim G, Maher VE, et al. Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: US Food and Drug Administration drug approval summary. Clin Cancer Res. 2012;18:3722-3730.
5. Hart CD, De Boer RH. Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer. Onco Targets Ther. 2013;6:1-7.
6. Wells SA Jr, Santoro M. Targeting the RET pathway in thyroid cancer. Clin Cancer Res. 2009;15:7119-7123.
7. Lanzi C, Cassinelli G, Nicolini V, Zunino F. Targeting RET for thyroid cancer therapy. Biochem Pharmacol. 2009;77:297-309.
8. Antonelli A, Fallahi P, Ferrari SM, et al. RET TKI: potential role in thyroid cancers. Curr Oncol Rep. 2012;14:97-104.
9. Borrello MG, Ardini E, Locati LD, Greco A, Licitra L, Pierotti MA. RET inhibition: implications in cancer therapy. Expert Opin Ther Targets. 2013;17:403-419.
10. Arighi E, Borrello MG, Sariola H. RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor Rev. 2005;16: 441-467.
11. Petrangolini G, Cuccuru G, Lanzi C, et al. Apoptotic cell death induction and angiogenesis inhibition in large established medullary thyroid carcinoma xenografts by Ret inhibitor RPI-1. Biochem Pharmacol. 2006;72:405-414.
12. Koga K, Hattori Y, Komori M, et al. Combination of RET siRNA and irinotecan inhibited the growth of medullary thyroid carcinoma TT cells and xenografts via apoptosis. Cancer Sci. 2010;101:941-947.
13. Schmidt A, Eipel C, Fürst K, Sommer N, Pahnke J, Pützer BM. Evaluation of systemic targeting of RET oncogene-basedMTCwith tumor-selective peptide-Tagged Ad vectors in clinical mouse models. Gene Ther. 2011;18:418-423.
14. Bredesen DE, Mehlen P, Rabizadeh S. Apoptosis and dependence receptors: a molecular basis for cellular addiction. Physiol Rev. 2004;84:411-430.
15. Weinstein IB, Joe AK. Mechanisms of disease: oncogene addiction-A rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol. 2006;3:448-457.
16. Sharma SV, Settleman J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev. 2007;21:3214-3231.
17. Drosten M, Hilken G, Böckmann M, et al. Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma. J Natl Cancer Inst. 2004;96:1231-1239.
18. Nicolini V, Cassinelli G, Cuccuru G, et al. Interplay between Ret and Fap-1 regulates CD95-mediated apoptosis in medullary thyroid cancer cells. Biochem Pharmacol. 2011;82:778-788.
19. Carr LL, Mankoff DA, Goulart BH, et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res. 2010;16:5260-5268.
20. Cepeda V, Fuertes MA, Castilla J, Alonso C, Quevedo C, Pérez JM. Biochemical mechanisms of cisplatin cytotoxicity. Anticancer Agents Med Chem. 2007;7:3-18.
21. Spierings DC, de Vries EG, Vellenga E, de Jong S. Loss of druginduced activation of the CD95 apoptotic pathway in a cisplatinresistant testicular germ cell tumor cell line. Cell Death Differ. 2003; 10:808-822.
22. Lacour S, Hammann A, Grazide S, et al. Cisplatin-induced CD95 redistribution into membrane lipid rafts of HT29 human colon cancer cells. Cancer Res. 2004;64:3593-3598.
23. Sancho-Martínez SM, Prieto-García L, Prieto M, López-Novoa JM, López-Hernández FJ. Subcellular targets of cisplatin cytotoxicity: an integrated view. Pharmacol Ther. 2012;136:35-55.
24. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9:327-337.
25. Mitsiades N, Poulaki V, Tseleni-Balafouta S, Koutras DA, Stamenkovic I. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res. 2000;60:4122-4129.
26. Cincinelli R, Cassinelli G, Dallavalle S, et al. Synthesis, modeling, and RET protein kinase inhibitory activity of 3-And 4-substituted -carbolin-1-ones. J Med Chem. 2008;51:7777-7787.
27. Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol. 2007;25:884-896.
28. Rapa I, Saggiorato E, Giachino D, et al. Mammalian target of rapamycin pathway activation is associated to RET mutation status in medullary thyroid carcinoma. J Clin Endocrinol Metab. 2011;96: 2146-2153.
29. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70:440-446.
30. Wu WK, Coffelt SB, Cho CH, et al. The autophagic paradox in cancer therapy. Oncogene. 2012;31:939-953.
31. Klionsky DJ, Abdalla FC, Abeliovich H, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2012;8:445-544.
32. Kepp O, Galluzzi L, Lipinski M, Yuan J, Kroemer G. Cell death assays for drug discovery. Nat Rev Drug Discov. 2011;10:221-237.
33. Gotink KJ, Broxterman HJ, Labots M, et al. Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. Clin Cancer Res. 2011;17:7337-7346.
34. Turk B, Turk V. Lysosomes as "suicide bags" in cell death: myth or reality? J Biol Chem. 2009;284:21783-21787.
35. Paul I, Chacko AD, Stasik I, et al. Acquired differential regulation of caspase-8 in cisplatin-resistant non-small-cell lung cancer. Cell Death Dis. 2012;3:e449.
36. Broutin S, Ameur N, Lacroix L, et al. Identification of soluble candidate biomarkers of therapeutic response to sunitinib in medullary thyroid carcinoma in preclinical models. Clin Cancer Res. 2011;17: 2044-2054.
37. Lin CI, Whang EE, Lorch JH, Ruan DT. Autophagic activation potentiates the antiproliferative effects of tyrosine kinase inhibitors in medullary thyroid cancer. Surgery. 2012;152:1142-1149.
38. Maiuri MC, Zalckvar E, Kimchi A, Kroemer G. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol. 2007;8:741-752.
39. Česen MH, Pegan K, Spes A, Turk B. Lysosomal pathways to cell death and their therapeutic applications. Exp Cell Res. 2012;318: 1245-1251.
40. Schlumberger M, Massicotte MH, Nascimento CL, Chougnet C, Baudin E, Leboulleux S. Kinase inhibitors for advanced medullary thyroid carcinoma. Clinics. 2012;67:125-129.